Ipsen has agreed to acquire U.S.-based clinical-stage biopharmaceutical company Kartos Therapeutics in a deal designed to strengthen its late-stage oncology pipeline, centered on navtemadlin, an investigational oral MDM2 inhibitor for myelofibrosis, a rare and serious blood cancer. The transaction includes an upfront cash payment of $450 million and up to $1.3 billion in potential milestone payments, with closing expected by the end of the third quarter of 2026, subject to customary conditions. Ipsen said the acquisition supports its strategy of expanding its oncology portfolio through externally sourced therapies with the potential to address significant unmet patient needs.
A Late-Stage Myelofibrosis Program
Navtemadlin is being developed as an add-on therapy to ruxolitinib for patients with intermediate- or high-risk TP53 wild-type myelofibrosis who have not achieved an adequate response to existing treatment. The therapy is designed to inhibit MDM2, a protein that can suppress p53, with the aim of restoring p53 activity and limiting the growth of abnormal cells. Kartos believes this approach could provide a new treatment option for patients whose disease remains uncontrolled despite standard care.
Myelofibrosis is a chronic blood cancer characterized by bone marrow scarring, reduced blood-cell production, spleen enlargement, and debilitating symptoms including fatigue, anemia, and bone pain. Ruxolitinib remains a commonly used treatment, but some patients experience an insufficient response or eventually discontinue therapy. Ipsen said the limited options available after ruxolitinib failure highlight the need for additional treatment approaches in this patient population.
Phase III Development Plans
The acquisition gives Ipsen control of navtemadlin as it advances through the global Phase III POIESIS trial. The study is expected to enroll more than 600 patients at over 250 sites and is evaluating navtemadlin plus ruxolitinib against ruxolitinib alone. Ipsen expects topline data in 2027, which could support a potential launch in 2028 if the trial delivers positive results and regulatory requirements are met.
Earlier Phase Ib and Phase II data informed the decision to progress the program into late-stage development. In patients with myelofibrosis who had shown an inadequate response to ruxolitinib, the combination of navtemadlin and ruxolitinib demonstrated reductions in spleen volume and improvements in symptom scores after 24 weeks of treatment. The preliminary findings also pointed to potential disease-modifying effects, including reductions in driver mutation burden and improvements in bone marrow fibrosis among evaluable patients.
Financial Terms and Strategic Rationale
Under the agreement, Ipsen will make an upfront cash payment of $450 million to acquire Kartos, while shareholders may receive additional payments tied to regulatory approvals and commercial milestones. The company said the total potential consideration could reach $1.75 billion if all milestone conditions are achieved. Ipsen expects the transaction to be accretive to core operating income from 2029 and to have limited impact on its financial outlook for 2026.
The deal advances Ipsen’s broader strategy of adding differentiated late-stage therapies across oncology, rare disease, and neuroscience. Navtemadlin would expand the company’s presence in hemato-oncology and provide exposure to a disease area where the clinical burden remains high and treatment choices are limited. The acquisition also reflects continued interest among larger drugmakers in securing promising clinical assets before they reach pivotal regulatory milestones.
Kartos and the Path Ahead
Kartos Therapeutics has focused on therapies targeting the p53 pathway, particularly in myeloproliferative neoplasms such as myelofibrosis. Its lead program is intended to improve outcomes for patients receiving ruxolitinib without requiring a complete switch away from their existing treatment. By bringing Kartos into its portfolio, Ipsen will assume responsibility for completing the pivotal study and preparing for potential regulatory submissions.
The company’s ability to realize the deal’s full value will depend on POIESIS trial outcomes, regulatory decisions, and eventual adoption by physicians and patients. Competition in myelofibrosis treatment is increasing, which means navtemadlin will need to show clinically meaningful benefits and a manageable safety profile. Still, the acquisition gives Ipsen a potentially important late-stage asset in a difficult-to-treat blood cancer market.
Ipsen’s acquisition of Kartos Therapeutics represents a major investment in its oncology pipeline and a targeted push into myelofibrosis treatment. The deal is built around navtemadlin’s potential to address patients who remain underserved by current ruxolitinib-based care. With pivotal data expected in 2027, the program will be closely watched as Ipsen seeks to convert a promising clinical asset into a new commercial growth driver.